Robust isolation of malignant plasma cells in multiple myeloma.

Ildiko Frigyesi, Jörgen Adolfsson, Mina Ali, Mikael Kronborg Christophersen, Ellinor Johnsson, Ingemar Turesson, Urban Gullberg, Markus Hansson, Björn Nilsson

Research output: Contribution to journalArticlepeer-review


Molecular characterization of malignant plasma cells is increasingly important for diagnostic and therapeutic stratification in multiple myeloma (MM). However, the malignant plasma cells represent a relatively small subset of bone marrow cells, and need to be enriched prior to analysis. Currently, the cell surface marker CD138 (SDC1) is used for this enrichment, but has an important limitation in that its expression decreases rapidly after sampling. Seeking alternatives to CD138, we performed a computational screen for myeloma plasma cell markers and evaluated seven candidates systematically. Our results conclusively show that the markers CD319 (SLAMF7/CS1) and CD269 (TNFRSF17/BCMA) are considerably more robust than CD138, and enable isolation of myeloma plasma cells under more diverse conditions, including in samples that have been delayed or frozen. Our results form the basis of improved procedures for characterizing cases of multiple myeloma in clinical practice.
Original languageEnglish
Pages (from-to)1336-1340
Issue number9
Publication statusPublished - 2014

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Division of Clinical Genetics (013022003), Emergency medicine/Medicine/Surgery (013240200), Division of Hematology and Transfusion Medicine (013041100)

Subject classification (UKÄ)

  • Hematology


Dive into the research topics of 'Robust isolation of malignant plasma cells in multiple myeloma.'. Together they form a unique fingerprint.

Cite this